XLHealth has been at the forefront of disease management innovations since its inception. Founded by physicians, many of whom were affiliated with Johns Hopkins, XLHealth’s unique approach to disease management has resulted in positive health care outcomes while lowering heath care costs.
XLHealth’s disease management model goes beyond telephone communications with patients. The firm’s approach is based upon the belief that one of the best ways to assess a patient’s condition is to have medical personnel conduct evaluations in person. The firm is a recognized pioneer in its delivery of disease management services in a personal, “high touch” way to support physicians in increasing the quality of care and eliminating unnecessary barriers to preventive treatment.
Given that physicians have been an integral part of the company’s operations, XLHealth disease management emphasizes the critical importance of the role physicians have in the health care equation. In fact, the premise upon which XLHealth is predicated is that disease management and support programs are most effective when they establish strong ties with the local health care community. Additionally, the health care professionals who manage XLHealth have shown that being close to physicians and their patients reaps significant results – in the quality of support that the firm can offer and in the cost savings that result.
In 2003, the United States Department of Health and Human Services and the Centers for Medicare and Medicaid Services (CMS) awarded XLHealth one of three demonstration projects in the nation to test whether disease management will improve the care of chronically ill Medicare patients. XLHealth developed a unique process that resulted in the recruitment of 13,000 patients for the pilot and 7,000 for a control group in less than one year.
XLHealth continues to be selected by organizations in both the public and private sectors to provide its unique disease management approach. In fact, the firm has more than doubled the number of its employees and is generating a more than 10-fold increase in revenues during the last 12-month period.
CMS, for instance, selected XLHealth for the Voluntary Chronic Care Improvement program (CCIP) in Tennessee, a major new initiative to help improve the quality of care for chronically ill beneficiaries under Medicare fee for service. XLHealth will be responsible for recruiting and offering disease management services to Medicare fee-for-service beneficiaries with diabetes, congestive heart failure and all related co-morbidities.
XLHealth has also closed on a private placement of $63,750,000 of Preferred Stock and related options with GS Capital Partners 2000, L.P., a private equity fund managed by Goldman, Sachs & Co., and to Dr. Norman Payson, the former Chairman and Chief Executive Officer of Oxford Health Plans. The investment represents one of the largest capital financing transactions in the growing disease management sector and marks Goldman Sachs Capital Partners’ entry into the field.
XLHealth has been awarded the Disease Management Association of America’s (DMAA) Recognizing Excellence Award for “Best Disease Management Program: Medicare.” The Disease Management Purchasing Consortium International also recently recognized XLHealth for “Best Disease management Ideas for 2005” for its approach to medication management.